20 results about "Mesothelioma" patented technology

This disclosure is directed to two cancer-associated fibroblast (CAP) subtypes, namely permissive (permCAF) and restraining (restCAF), in pancreatic ductal adenocarcinoma (PDAC), mesothelioma, urothelial carcinoma, or renal cell carcinoma. Methods are disclosed that describe how to identify a tumor sample as a perCAF or a restCAF subtypes. Methods are also disclosed that use the subtypes for diagnosis, prognosis, differential treatment, and treatment.

The invention relates to a specific antibody aiming at CD228 protein and an antigen binding fragment thereof, which are used for detecting and treating various tumors, such as melanoma, mesothelioma, colorectal cancer and the like. The antibody binding fragment is helpful for diagnosis and treatment of cancers through specific binding with CD228. The invention further comprises antibody drug conjugates (ADCs) which bind a drug to an antibody through a linker, so as to improve the therapeutic effect and reduce the influence on normal cells. Meanwhile, nucleic acids encoding the antibodies or antigen-binding fragments thereof are provided to produce recombinant antibodies or fragments. Besides, the invention also provides a kit which is used for laboratory research, clinical diagnosis and treatment effect monitoring, is beneficial to determining whether tissues or cells express CD228 or not, and provides a new strategy for personalized and precise treatment of cancers.

The present invention relates to therapeutic treatment of cancer, particularly mesothelioma, using Compound IA as single agent or in combination therapy using Compound IA and atezolizumab.

Provided is a therapeutic agent for malignant mesothelioma and a method for selecting a patient with malignant mesothelioma that expresses a large amount of oxytocin receptor. The therapeutic agent for malignant mesothelioma contains a compound that targets the oxytocin receptor as an active ingredient, thereby solving the problem.

The invention relates to a tricyclic heterocyclic compound as well as a preparation method and medical application thereof. Specifically, the invention relates to a compound shown in a general formula (I), a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound as an MAT2A inhibitor. The compound and the pharmaceutical composition containing the compound can be used for treating and / or preventing diseases related to MAT2A activity, such as mesothelioma, neuroblastoma, rectal cancer, colon cancer, esophageal cancer and the like. Wherein the definition of each group in the general formula (I) is the same as that in the specification.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The disclosure provides binding agents (e.g., antibodies) against a human Hepatitis A virus cellular receptor 2 protein (TIM3), as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting Non-Small Cell Lung Cancer (NSCLC) and / or other types of lung cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) or other types of liver cancer, Renal cell carcinoma, malignant melanoma, gastro-intestinal cancer, colorectal cancer, urothelial carcinoma and other types of bladder cancer, mamma carcinoma and / or other types of breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, lymphoma / leukemia, malignant mesothelioma, or a cancer in another organ or cell type.

Provided herein are compounds and pharmaceutical compositions containing these compounds useful in the treatment of cancer, such as mesothelioma. In addition, provided herein are methods of treating cancer, such as mesothelioma, using these compounds or pharmaceutical compositions. Specific cancers include cancers mediated by YAP / TAZ, or cancers regulated by the interaction between YAP / TAZ and TEAD, such as mesothelioma.

This document provides methods and materials involved in assessing and / or treating a mammal (e.g., a human) having cancer. For example, methods and materials that can be used to identify a cancer as being likely to respond to one or more immune checkpoint inhibitors are provided. For example, methods and materials that can be used to identify a mammal having cancer as being likely to develop one or more immune-related adverse events (irAEs) are provided. Methods for treating a mammal (e.g., a human) having cancer (e.g., lung cancer such as mesothelioma) where the cancer treatment is selected based on whether or not the cancer is likely to be responsive to one or more immune checkpoint inhibitors and / or whether or not the mammal is likely to develop one or more irAEs are also provided.

To provide a treatment for malignant mesothelioma that can specifically kill cancer cells and has few side effects. [Solution] A therapeutic agent for malignant mesothelioma comprising cerurenin and / or its derivatives, or KN-93 and / or its derivatives, as an active ingredient.

This invention relates to the field of medicinal chemistry, and particularly to a small molecule inhibitor of TEAD and its use in drugs for TEAD receptor-related cancers. Seven compounds were identified as TEAD inhibitors through virtual screening, and one compound was ultimately determined to have inhibitory effects on TEAD cells. This compound can therefore serve as a lead compound for the preparation of drugs for treating mesothelioma and other diseases related to the TEAD target. Specifically, the compound is: N-(4-fluorophenyl)-6-methyl-2-[5-methyl-1-(4-methylphenyl)pyrazol-4-yl]quinoline-4-carboxamide. This invention effectively screens ligands that inhibit the TEAD receptor using a combination of the AutoGen software for automated molecule generation and bioactivity assays. These ligands can serve as lead compounds for the preparation of drugs for treating TEAD receptor-mediated diseases, especially mesothelioma, and can effectively treat TEAD receptor-related diseases and their complications.

This invention provides a stable passaged human mesothelioma cell line MESO-016, its construction method, and its application in tumor research and drug development. The cell line provided by this invention can be continuously passaged in vitro and possesses xenogeneic tumorigenesis ability. Tumors formed in nude mice exhibit the same pathological characteristics as the primary tumor tissue, making it suitable as a cell material for research on mesothelioma-related drugs and diagnostic reagents, as well as for studying the mechanisms of tumor development and progression.

Provided herein are nucleic acid constructs comprising a polynucleotide sequence encoding a TUSC2 protein. Also contemplated are non-viral and viral vectors comprising nucleic acid constructs disclosed herein. Non-viral vectors include, but are not limited, to DOTAP:cholesterol liposomes. Further contemplated herein are pharmaceutical compositions comprising the nucleic acid constructs or vectors disclosed herein and methods of using the nucleic acid constructs, vectors, or pharmaceutical compositions for the treatment of mesothelioma in a subject in need thereof. These methods can further include administering an additional anti-cancer therapy to the subject in need thereof.

The present invention addresses the issue of providing a malignant mesothelioma therapeutic agent and a method for selecting malignant mesothelioma patients. The issue can be solved by a malignant mesothelioma therapeutic agent that includes, as an effective component thereof, a compound that targets the oxytocin receptor.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological conditions including grade IV glioblastoma, grade 3 glioma, embryonal tumor, pituitary tumor, meningioma, hemangiopericytoma, hemangioblastoma, mesothelioma, cholangiocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urinary tract cancer, bladder adenocarcinoma, and esophageal cancer, as well as for use in the treatment of peripheral diabetic neuropathy, spinal cord injury, postherpetic neuralgia, chemotherapeutic agents, antitumor agents, cancer, fibromyalgia, or neuropathic pain caused by hepatitis. The present invention also relates to pharmaceutical compositions comprising 2-hydroxy-octadecene-9-cis-oate.

The present invention relates to therapeutic treatment of cancer, particularly mesothelioma, using ecubectedin (PM14) as single agent or in combination therapy using ecubectedin and atezolizumab.

A humanized antibody specifically recognizing human CA IX, and to therapeutic and diagnostic methods utilizing this antibody is disclosed. The methods relate in particular to treatment or diagnosis of cancers selected from squamous cell carcinoma, myeloma, small-cell lung cancer, non-small cell lung cancer, glioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal (tract) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, mesothelioma, and head and neck cancer.

The invention provides a mesothelioma prediction method based on CGAN-SVDD-DBN-ELM-BP, and the method comprises the steps: 1, obtaining the detection data of a mesothelioma patient, and carrying out the data preprocessing, and the data preprocessing comprises the filling of a missing value, the deletion of an abnormal value, and the normalization processing; 2, generating more patient samples based on mesothelioma definite diagnosis patient data and mesothelioma related characteristics by using a conditional generative adversarial network, and solving the problem of imbalance between data; 3, performing anomaly detection on the mesothelioma data after data enhancement through a support vector data description method, establishing a minimum hyper-sphere including as many training samples as possible, and removing abnormal data samples outside the hyper-sphere; and finally, using mesothelioma data after abnormal data elimination to train a DBN-ELM-BP deep learning algorithm, the algorithm combining DBN unsupervised feature extraction, ELM fast learning speed and generalization ability, solving the problems of slow convergence speed and falling into local minimum caused by parameter random initialization, effectively reducing training errors and generalization errors, and improving the robustness of the algorithm. And the prediction performance is improved. And classifying the samples by using the trained classifier and outputting a mesothelioma prediction result.

The present invention relates to a compound 2-hydroxy-octadecene-9-cis-acid for use in the treatment of tumor pathology, the tumor pathologies include grade IV glioblastoma with natural IDH, grade 3 glioma, embryonic tumor, pituitary tumor, meningioma, vascular epidermis cytoma, vascular blastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, umbilical urinary duct cancer, bladder adenocarcinoma, and esophageal cancer, as well as for the treatment of neuropathic pain. The neuropathic pain is caused by diabetic peripheral neuropathy, spinal cord injury, post-herpes zoster neuralgia, a chemotherapeutic agent, an antitumor agent, cancer, fibromyalgia or hepatitis. The present invention also relates to a pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-acid, and a pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-acid.

A prodrug nanoparticle for targeted accumulation and activation (treatment) in tumor tissue, that consists of a Pt(IV) complex with the following formula: wherein R1 und R2 are the same or different branched or unbranched alkyls having at least 14 carbon atoms, a sonosensitizer and a biocompatible drug delivery system can be used to treat tumors and in particular metastases in a way that is well tolerated by the body. The prodrug nanoparticles according to the invention are particularly suitable for the treatment of mammary carcinomas, pancreatic carcinomas, prostate carcinomas, bronchial carcinomas, endometrial carcinomas, germ cell tumors, non-Hodgkin's lymphomas and malignant mesotheliomas and, in particular, colorectal carcinomas, and their respective metastases.